Primary aldosteronism: diagnostic and therapeutic considerations.
Recent evaluations indicate that primary aldosteronism (PA) is common in patients with hypertension. In patients with mild to moderate hypertension the prevalence of PA is 5% to 10%, whereas in subjects with resistant hypertension the prevalence is approximately 20%. As such, PA has become the most common secondary cause of hypertension. Such high prevalence rates are distinctly different from earlier assessments in which PA was found to be rare, with a prevalence of generally less than 1% of hypertensive patients. Why PA is seemingly so much more common now than when first described remains unknown. Accurate identification of PA allows for specific therapy with aldosterone antagonists or with surgical resection of aldosterone-producing adenomas. Determination of the plasma aldosterone to plasma renin activity ratio is an effective screen for PA in that it has a high negative predictive value even in the setting of ongoing antihypertensive therapy. Its specificity, however, is low such that a high ratio is suggestive of PA but must be confirmed by demonstration of high and autonomous secretion of aldosterone.
Nishizaka
Mari K
MK
Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 430 BMR2, 1530 3rd Avenue South, Birmingham, AL 35294, USA.
Calhoun
David A
DA
D000315:Adrenalectomy / Q000379:methods*; D000450:Aldosterone / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000502:physiology; D003937:Diagnosis, Differential; D006801:Humans; D006929:Hyperaldosteronism / Q000097:blood / Q000175:diagnosis* / Q000628:therapy*; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D012083:Renin / Q000097:blood
D015415:Biomarkers; D000451:Mineralocorticoid Receptor Antagonists; D000450:Aldosterone; D012083:Renin